All In Biotech

Drug Trial Radar · NCT05141149

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer

A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 5, 2023

Primary completion

Jul 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Prestige Biopharma LimitedIndustry
Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1 as a PBP1510 single agent dose-escalation, and PBP1510 dose-escalation in combination with gemcitabine, and Part 2 as PBP1510 dose-expansion at the RP2D in combination with gemcitabine.

Conditions

  • Pancreatic Cancer

Interventions

  • PBP1510 (400mg/16mL)Drug

    Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion

  • Gemcitabine (1000 mg/m^2)Drug

    Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets and neutralizes PAUF, administered as a 90-minute intravenous infusion in combination with 1000 mg/m2 gemcitabine administered as a 30-minute intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PART 1 (PHASE 1): To evaluate safety and tolerability of PBP1510Time frame: Baseline to Safety Follow Up visit (90 days after last dose of PBP1510)
  2. PART 1 (PHASE 1): Dose limiting toxicity (DLT) evaluationTime frame: During first treatment cycle (each cycle is 28 days)
  3. PART 2 (PHASE 2a): To establish safety of PBP1510 in combination with gemcitabineTime frame: Baseline to Safety Follow Up visit (90 days after last dose of PBP1510)
  4. PART 2 (PHASE 2a): To assess the efficacy of PBP1510 in combination with gemcitabineTime frame: Baseline to End of Treatment visit (28 days after last dose of PBP1510)
  5. PART 1 (PHASE 1): Determine the recommended Phase 2a dose (R2PD) of PBP1510Time frame: After last patient enrolled in last dosing cohort completes 4 cycles of treatment. Each cycle is 28 days.

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Northwell Health / R.J. Zuckerberg Cancer Center

    New Hyde Park, New York

  • Monash Health

    Melbourne, Australia

  • National Cancer Centre Singapore

    Singapore, Singapore

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.